EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Reprogramming Immunologically Cold Tumors with Bioactive Gases: A Translational Perspective on Gasotransmitters and Cancer Immunotherapy

Vicente Javier Clemente-Suárez, José Francisco López-Gil, Rodrigo Yáñez-Sepúlveda

Cancers · 15.11.2026 · 18 (22) · 3651

DOI: 10.3390/cancers18223651 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancers, online erschienen am 15.11.2026. Verfasst von Vicente Javier Clemente-Suárez und 2 weiteren Autor:innen. Die Arbeit nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Immune checkpoint blockade (ICB) can restore antitumor T-cell activity, but immune-desert, immune-excluded, and T-cell-inflamed yet dysfunctional tumors present different forms of resistance. Nitric oxide (NO), carbon monoxide (CO), and hydrogen sulfide (H2S) are endogenous gasotransmitters that influence vascular function, redox signaling, metabolism, and immunity; molecular hydrogen (H2) is a distinct bioactive gas under investigation. This Perspective evaluates whether gas-based interventions can address specific barriers to ICB and differs from broad surveys of gas nanomedicines by linking tumor immune phenotypes to exposure verification, causal immune readouts, delivery design, and clinical decision gates. Effects depend on concentration, site, source, and duration and may suppress immunity. NO-releasing nanocarriers and multicomponent NO-generating nanoreactors have shown vascular and immune effects in preclinical systems, whereas a ten-patient phase I intratumoral NO report provides preliminary safety and feasibility information without controlled evidence of clinical efficacy. CO and H2S strategies remain predominantly preclinical, and human H2 findings are exploratory. We distinguish biomarkers of gas exposure and target engagement from immune remodeling and patient benefit, discuss molecular imaging and microbiome-related confounding, and propose mechanism-matched combination schedules and safety requirements. Gas-based treatment should therefore be tested against predefined resistance mechanisms rather than presumed to convert all cold tumors into ICB-responsive lesions.

Zitieren

APA

Clemente-Suárez, V. J., López-Gil, J. F., & Yáñez-Sepúlveda, R. (2026). Reprogramming Immunologically Cold Tumors with Bioactive Gases: A Translational Perspective on Gasotransmitters and Cancer Immunotherapy. Cancers, 18(22), 3651. https://doi.org/10.3390/cancers18223651

Vancouver

Clemente-Suárez VJ, López-Gil JF, Yáñez-Sepúlveda R. Reprogramming Immunologically Cold Tumors with Bioactive Gases: A Translational Perspective on Gasotransmitters and Cancer Immunotherapy. Cancers. 2026;18(22):3651. doi:10.3390/cancers18223651

BibTeX
@article{ClementeSurez2026,
  author = {Clemente-Suárez, Vicente Javier and López-Gil, José Francisco and Yáñez-Sepúlveda, Rodrigo},
  title = {Reprogramming Immunologically Cold Tumors with Bioactive Gases: A Translational Perspective on Gasotransmitters and Cancer Immunotherapy},
  journal = {Cancers},
  year = {2026},
  volume = {18},
  number = {22},
  pages = {3651},
  doi = {10.3390/cancers18223651}
}
Kostenlos starten →